Investors in Health

WestTech Ventures, a Berlin-based investment firm, partners with emerging VC funds in Europe and pre-seed & seed startups in Germany dedicated to making a positive global impact through technology.

Ethias Ventures is the venture capital arm of Ethias group. Investing in innovative start-ups relevant in insurance ecosystem is our leitmotif. Beyond investments, we create partnership opportunities with Ethias insurance business to accelerate your growth. Because we believe in win-win investments ! We are currently looking for European start-ups, with visible traction, and scale-ups in InsurTech and in the ecosystems related to insurance : Mobility, Health and Property. With Ethias Ventures, you can rely on our rich expertise and strong position in Belgian insurance market : • #1 Direct Insurer with 1.2 Mios B2C customers, 46.5K B2B customers (#1 public sector), • financial strength : Fitch rating A (May 2022).

Masawa invests in European startups catalyzing mental health and wellness. Our Nurture Capital approach minimizes risk, enhances founder wellbeing, repurposes capital, and optimizes financial and social returns.

The first NHS-founded and backed venture fund for digital health and MedTech. Accelerating the future of healthcare in the UK and beyond.

Martlet Capital provides early stage patient capital and support. We look to help founders and ventures grow by providing added value beyond money. This may include helping companies build teams and boards, advising on strategy, connections to technical experts, customers and investors, as well as being part of the community of our portfolio companies. We always co-invest alongside others, such as angels, seed funds and VC’s. We usually invest upwards of £250k in a first round and have the capacity to follow on in subsequent investment rounds.

Early-stage Fintech, DeepTech, and x-Tech investment across the UK, Europe, MNA, and APAC regions. We’re a UK based fund with a genuine curiosity for new challenges that have potential to expand to other continents, having backed founders from diverse backgrounds. Good ideas know no borders. And neither do our investments.

Actio Capital Ventures is a boutique investment firm dedicated to fueling the growth of innovative startups and empowering entrepreneurs to transform their bold ideas into reality. Founded by experienced entrepreneurs Eric and Zulfukar, we are passionate about supporting businesses at the pre-seed stage of their development.

Big ideas don’t scare us — to the contrary, we’re energized by investing early in founders with huge visions. That’s why we start investing at Pre-Seed, Seed, and Series A — and continue to support companies as their ideas shift and grow. Tomorrow’s most iconic companies will defy categorization and create sectors of their own — that’s why we stay open-minded in our approach and are getting behind founding teams building at the edge of more than one category. We’re investing in our portfolio companies across their lifecycle. Our three sequential funds are designed to make Valia a long-term partner to founders as their funding needs expand.

Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. Gilde Healthcare is headquartered in Utrecht (the Netherlands) with local offices in Frankfurt (Germany) and Boston (USA). Gilde Healthcare differentiates itself through its deep sector knowledge in healthcare, which has been acquired during the past decades. The investment team consisting of industry experts, ex-consultants and investors provides hands-on support to its managers in designing the growth strategy and by contributing domain expertise. Gilde Healthcare believes optimal value creation in healthcare is associated with better care at lower cost.

In a nutshell, Commercialization Reactor is a platform with a mission to commercialize science via a specific paradigm: Bring Scientists and Entrepreneurs together to co-create Deep-Tech startup aimed to commercialize the Core Competence of the Scientific Team. The Entrepreneurs become responsible to fulfill business leadership-related activities, taking into a full-time focus and Scientists focus exclusively on their core competence and inhale their knowledge and skills into a product or service that Entrepreneurial Team sets as a vector for business development strategy. This paradigm of commercialization together with over 10 years of experience in creating, pre-incubating and accelerating startups currently resulted in over 100 fully-formed Science-based startup companies born in CR. Most of those received investments are from various venture funds across the globe. Ultimately, this leads to unique Science-based startup creation and performance scoring methodology that is a core know-how of Commercialization Reactor. The methodology is proven successful by a fact of an exit, which already is in the arsenal of achievements of the CR Team.

The Joint Polish Investment Fund, ("JPIF") is a new Life Science Venture Capital Fund, which focuses on investments in Life Science companies with visible and near-term value inflection points and a prospective holding period of 3-5 years. JPIF consists of a team of people with broad experience in the life-science sector. Scientists and medical doctors with industrial experience work hand in glove with colleagues who have a thorough training in economics and business affairs. Everybody is driven by true interest in the life science field and new technologies, which will greatly contribute to people’s health disease management and quality of life. Entrepreneurs backed by JPIF have access to the knowledge and advice of each member of the JPIF team and to the associated global scientific and commercial network. Together JPIF and entrepreneurs are therefore in the position to accelerate preclinical, clinical or commercial development and a successful market entry into the most important healthcare markets: Europe, the U.S., and Asia.

Scientipole Ile-de-France Capital is a French venture capital firm specialized in funding seed stage companies. Scientipôle Capital invests in the innovative tech-based startups, at early stage. Team keeps a close relationship during the entire investment period to help entrepreneurs to succeed in all areas of management Scientipôle Capital is focused on innovative technologies developed in the Paris-Saclay area: • Solutions for the industry 4.0 : digital technologies, industrial technologies • Green tech applications to support energy and ecological transitions - smart grid, smart city • Health / medtech (except drugs) ...